Literature DB >> 9708551

Beneficial effects of L-serine and glycine in the management of seizures in 3-phosphoglycerate dehydrogenase deficiency.

T J de Koning1, M Duran, L Dorland, R Gooskens, E Van Schaftingen, J Jaeken, N Blau, R Berger, B T Poll-The.   

Abstract

3-Phosphoglycerate dehydrogenase (3-PGDH) deficiency is an inborn error of serine biosynthesis. Patients are affected with congenital microcephaly, psychomotor retardation, and intractable seizures. The effects of oral treatment with amino acids were investigated in 2 siblings. L-Serine up to 500 mg/kg/day was not sufficient for seizure control. Addition of glycine 200 mg/kg/day resulted in complete disappearance of seizures. Electroencephalographic abnormalities gradually resolved after 6 months. We conclude that 3-PGDH can be treated effectively by a combination of L-serine and glycine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9708551     DOI: 10.1002/ana.410440219

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  24 in total

1.  Branch-point stoichiometry can generate weak links in metabolism: the case of glycine biosynthesis.

Authors:  Enrique Melendez-Hevia; Patricia De Paz-Lugo
Journal:  J Biosci       Date:  2008-12       Impact factor: 1.826

2.  L-Serine Deficiency Elicits Intracellular Accumulation of Cytotoxic Deoxysphingolipids and Lipid Body Formation.

Authors:  Kayoko Esaki; Tomoko Sayano; Chiaki Sonoda; Takumi Akagi; Takeshi Suzuki; Takuya Ogawa; Masahiro Okamoto; Takeo Yoshikawa; Yoshio Hirabayashi; Shigeki Furuya
Journal:  J Biol Chem       Date:  2015-04-22       Impact factor: 5.157

3.  A weak link in metabolism: the metabolic capacity for glycine biosynthesis does not satisfy the need for collagen synthesis.

Authors:  Enrique Meléndez-Hevia; Patricia De Paz-Lugo; Athel Cornish-Bowden; María Luz Cárdenas
Journal:  J Biosci       Date:  2009-12       Impact factor: 1.826

4.  A yeast-based complementation assay elucidates the functional impact of 200 missense variants in human PSAT1.

Authors:  Amy Sirr; Russell S Lo; Gareth A Cromie; Adrian C Scott; Julee Ashmead; Mirutse Heyesus; Aimée M Dudley
Journal:  J Inherit Metab Dis       Date:  2020-02-27       Impact factor: 4.982

5.  Glycine receptors support excitatory neurotransmitter release in developing mouse visual cortex.

Authors:  Portia A Kunz; Alain C Burette; Richard J Weinberg; Benjamin D Philpot
Journal:  J Physiol       Date:  2012-09-17       Impact factor: 5.182

6.  Molecular characterization of 3-phosphoglycerate dehydrogenase deficiency--a neurometabolic disorder associated with reduced L-serine biosynthesis.

Authors:  L W Klomp; T J de Koning; H E Malingré; E A van Beurden; M Brink; F L Opdam; M Duran; J Jaeken; M Pineda; L Van Maldergem; B T Poll-The; I E van den Berg; R Berger
Journal:  Am J Hum Genet       Date:  2000-10-27       Impact factor: 11.025

7.  3-Phosphoglycerate dehydrogenase, a key enzyme for l-serine biosynthesis, is preferentially expressed in the radial glia/astrocyte lineage and olfactory ensheathing glia in the mouse brain.

Authors:  M Yamasaki; K Yamada; S Furuya; J Mitoma; Y Hirabayashi; M Watanabe
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

8.  On the phenotypic spectrum of serine biosynthesis defects.

Authors:  Ayman W El-Hattab; Ranad Shaheen; Jozef Hertecant; Hassan I Galadari; Badi S Albaqawi; Amira Nabil; Fowzan S Alkuraya
Journal:  J Inherit Metab Dis       Date:  2016-03-10       Impact factor: 4.982

9.  Neutral amino acid transporter ASCT1 is preferentially expressed in L-Ser-synthetic/storing glial cells in the mouse brain with transient expression in developing capillaries.

Authors:  Kazuhisa Sakai; Hidemi Shimizu; Tatsuro Koike; Shigeki Furuya; Masahiko Watanabe
Journal:  J Neurosci       Date:  2003-01-15       Impact factor: 6.167

Review 10.  L-serine in disease and development.

Authors:  Tom J de Koning; Keith Snell; Marinus Duran; Ruud Berger; Bwee-Tien Poll-The; Robert Surtees
Journal:  Biochem J       Date:  2003-05-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.